Patient-derived organoids for hepatobiliary cancers: Molecular mechanisms, translational applications and precision therapeutics
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218810 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026. Verfasst von Senyan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; International Cooperation Laboratory …. Hauptthemen laut MEDLINE: Organoids, Precision Medicine, Liver Neoplasms, Biliary Tract Neoplasms. Die Arbeit nennt 115 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatobiliary cancers are highly heterogeneous malignant tumors, and the drug resistance frequently emerges at advanced stages. Patient-derived organoids (PDOs) are three-dimensional ex vivo cultures. They can reproduce essential biological aspects of primary tumors, and play a key role in personalized oncology. With advances in methodology and technology, PDOs are increasingly being used in hepatobiliary cancer research at both the fundamental and translational levels. This review summarizes recent advances in patient-derived organoids, including culture matrices, microenvironment reconstruction, and organoid-on-chips. We also discuss the applications of PDOs in hepatobiliary cancer modeling and organoid biobank construction. Hepatobiliary cancer organoids hold promise for drug development and may serve as complementary tools for preclinical prediction. Integrating in vitro drug testing, resistance mechanism identification and combination regimen screening, organoid-based workflows can provide platforms for treatment stratification and personalized treatment optimization in hepatobiliary cancers. The incorporation of artificial intelligence may further expand the capabilities of organoid-based platforms. Overall, hepatobiliary cancer organoids represent clinically promising models for overcoming therapeutic resistance and developing personalized treatment strategies. They are powerful tools for precision oncology and clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; International Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Ministry of…
- Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; The First Clinical School of Medicine, Zhengzhou University, Zhengzhou, 450052, China. Electronic address:…
- Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University,…
- International Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Ministry of Education Key Laboratory on Signaling Regulation and Targeting Therapy of Liver Cancer, Shanghai Key Laboratory…
- Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Department of Oncology, Henan Cancer Hospital, Zhengzhou University Affiliated Cancer Hospital, Zhengzhou,…
Förderung
- Science and Technology Commission of Shanghai Municipality
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Henan Provincial Science and Technology Research Project
Zitieren
APA
Wang, S., Liu, Y., Liu, Q., Zhang, M., Bai, X., Li, X., Jin, C., Sun, X., Xu, J., Zhao, X., Fu, J., & Wang, H. (2026). Patient-derived organoids for hepatobiliary cancers: Molecular mechanisms, translational applications and precision therapeutics. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218810
Vancouver
Wang S, Liu Y, Liu Q, Zhang M, Bai X, Li X, et al. Patient-derived organoids for hepatobiliary cancers: Molecular mechanisms, translational applications and precision therapeutics. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218810
BibTeX
@article{Wang2026,
author = {Wang, Senyan and Liu, Yixuan and Liu, Qi and Zhang, Mengzhen and Bai, Xinhan and Li, Xinze and Jin, Chongwei and Sun, Xiaoyan and Xu, Jing and Zhao, Xiaofang and Fu, Jing and Wang, Hongyang},
title = {Patient-derived organoids for hepatobiliary cancers: Molecular mechanisms, translational applications and precision therapeutics},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218810}
}
EUVIMED